Remdesivir for the treatment of COVID-19
- PMID: 36695483
- PMCID: PMC9875553
- DOI: 10.1002/14651858.CD014962.pub2
Remdesivir for the treatment of COVID-19
Abstract
Background: Remdesivir is an antiviral medicine approved for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19). This led to widespread implementation, although the available evidence remains inconsistent. This update aims to fill current knowledge gaps by identifying, describing, evaluating, and synthesising all evidence from randomised controlled trials (RCTs) on the effects of remdesivir on clinical outcomes in COVID-19.
Objectives: To assess the effects of remdesivir and standard care compared to standard care plus/minus placebo on clinical outcomes in patients treated for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Search methods: We searched the Cochrane COVID-19 Study Register (which comprises the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, ClinicalTrials.gov, World Health Organization (WHO) International Clinical Trials Registry Platform, and medRxiv) as well as Web of Science (Science Citation Index Expanded and Emerging Sources Citation Index) and WHO COVID-19 Global literature on coronavirus disease to identify completed and ongoing studies, without language restrictions. We conducted the searches on 31 May 2022.
Selection criteria: We followed standard Cochrane methodology. We included RCTs evaluating remdesivir and standard care for the treatment of SARS-CoV-2 infection compared to standard care plus/minus placebo irrespective of disease severity, gender, ethnicity, or setting. We excluded studies that evaluated remdesivir for the treatment of other coronavirus diseases.
Data collection and analysis: We followed standard Cochrane methodology. To assess risk of bias in included studies, we used the Cochrane RoB 2 tool for RCTs. We rated the certainty of evidence using the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach for outcomes that were reported according to our prioritised categories: all-cause mortality, in-hospital mortality, clinical improvement (being alive and ready for discharge up to day 28) or worsening (new need for invasive mechanical ventilation or death up to day 28), quality of life, serious adverse events, and adverse events (any grade). We differentiated between non-hospitalised individuals with asymptomatic SARS-CoV-2 infection or mild COVID-19 and hospitalised individuals with moderate to severe COVID-19.
Main results: We included nine RCTs with 11,218 participants diagnosed with SARS-CoV-2 infection and a mean age of 53.6 years, of whom 5982 participants were randomised to receive remdesivir. Most participants required low-flow oxygen at baseline. Studies were mainly conducted in high- and upper-middle-income countries. We identified two studies that are awaiting classification and five ongoing studies. Effects of remdesivir in hospitalised individuals with moderate to severe COVID-19 With moderate-certainty evidence, remdesivir probably makes little or no difference to all-cause mortality at up to day 28 (risk ratio (RR) 0.93, 95% confidence interval (CI) 0.81 to 1.06; risk difference (RD) 8 fewer per 1000, 95% CI 21 fewer to 6 more; 4 studies, 7142 participants), day 60 (RR 0.85, 95% CI 0.69 to 1.05; RD 35 fewer per 1000, 95% CI 73 fewer to 12 more; 1 study, 1281 participants), or in-hospital mortality at up to day 150 (RR 0.93, 95% CI 0.84 to 1.03; RD 11 fewer per 1000, 95% CI 25 fewer to 5 more; 1 study, 8275 participants). Remdesivir probably increases the chance of clinical improvement at up to day 28 slightly (RR 1.11, 95% CI 1.06 to 1.17; RD 68 more per 1000, 95% CI 37 more to 105 more; 4 studies, 2514 participants; moderate-certainty evidence). It probably decreases the risk of clinical worsening within 28 days (hazard ratio (HR) 0.67, 95% CI 0.54 to 0.82; RD 135 fewer per 1000, 95% CI 198 fewer to 69 fewer; 2 studies, 1734 participants, moderate-certainty evidence). Remdesivir may make little or no difference to the rate of adverse events of any grade (RR 1.04, 95% CI 0.92 to 1.18; RD 23 more per 1000, 95% CI 46 fewer to 104 more; 4 studies, 2498 participants; low-certainty evidence), or serious adverse events (RR 0.84, 95% CI 0.65 to 1.07; RD 44 fewer per 1000, 95% CI 96 fewer to 19 more; 4 studies, 2498 participants; low-certainty evidence). We considered risk of bias to be low, with some concerns for mortality and clinical course. We had some concerns for safety outcomes because participants who had died did not contribute information. Without adjustment, this leads to an uncertain amount of missing values and the potential for bias due to missing data. Effects of remdesivir in non-hospitalised individuals with mild COVID-19 One of the nine RCTs was conducted in the outpatient setting and included symptomatic people with a risk of progression. No deaths occurred within the 28 days observation period. We are uncertain about clinical improvement due to very low-certainty evidence. Remdesivir probably decreases the risk of clinical worsening (hospitalisation) at up to day 28 (RR 0.28, 95% CI 0.11 to 0.75; RD 46 fewer per 1000, 95% CI 57 fewer to 16 fewer; 562 participants; moderate-certainty evidence). We did not find any data for quality of life. Remdesivir may decrease the rate of serious adverse events at up to 28 days (RR 0.27, 95% CI 0.10 to 0.70; RD 49 fewer per 1000, 95% CI 60 fewer to 20 fewer; 562 participants; low-certainty evidence), but it probably makes little or no difference to the risk of adverse events of any grade (RR 0.91, 95% CI 0.76 to 1.10; RD 42 fewer per 1000, 95% CI 111 fewer to 46 more; 562 participants; moderate-certainty evidence). We considered risk of bias to be low for mortality, clinical improvement, and safety outcomes. We identified a high risk of bias for clinical worsening.
Authors' conclusions: Based on the available evidence up to 31 May 2022, remdesivir probably has little or no effect on all-cause mortality or in-hospital mortality of individuals with moderate to severe COVID-19. The hospitalisation rate was reduced with remdesivir in one study including participants with mild to moderate COVID-19. It may be beneficial in the clinical course for both hospitalised and non-hospitalised patients, but certainty remains limited. The applicability of the evidence to current practice may be limited by the recruitment of participants from mostly unvaccinated populations exposed to early variants of the SARS-CoV-2 virus at the time the studies were undertaken. Future studies should provide additional data on the efficacy and safety of remdesivir for defined core outcomes in COVID-19 research, especially for different population subgroups.
Trial registration: ClinicalTrials.gov NCT04280705 NCT04501952 NCT04292730 NCT04257656 NCT04330690 NCT04321616 NCT04315948 NCT04647669 NCT05024006 NCT04345419 NCT04596839 NCT04745351 NCT04252664 NCT04843761 NCT04978259.
Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Conflict of interest statement
FG: works as an Intensive Care Medicine Consultant and is member of the CEOsys project. The latter was funded in 2021 by the Network of University Medicine (Nationales Forschungsnetzwerk der Universitätsmedizin (NUM)) by the Federal Ministry of Education and Research of Germany (Bundesministerium für Bildung und Forschung (BMBF)), grant number 01KX2021, paid to the institution.
KA: is member of the CEOsys project, which was funded in 2021 by the Network of University Medicine (Nationales Forschungsnetzwerk der Universitätsmedizin (NUM)) by the Federal Ministry of Education and Research of Germany (Bundesministerium für Bildung und Forschung (BMBF)), grant number 01KX2021, paid to the institution.
KD: is member of the CEOsys project, which was funded in 2021 by the Network of University Medicine (Nationales Forschungsnetzwerk der Universitätsmedizin (NUM)) by the Federal Ministry of Education and Research of Germany (Bundesministerium für Bildung und Forschung (BMBF)), grant number 01KX2021, paid to the institution.
VT: works as an Intensive Care Medicine Consultant and is member of the CEOsys project (no direct funding).
MIM: is member of the CEOsys project, which was funded in 2021 by the Network of University Medicine (Nationales Forschungsnetzwerk der Universitätsmedizin (NUM)) by the Federal Ministry of Education and Research of Germany (Bundesministerium für Bildung und Forschung (BMBF)), grant number 01KX2021, paid to the institution. MIM is part of Cochrane Metabolic and Endocrine Disorders; she was not part of the editorial process.
NS: none known; she is Co‐ordinating Editor of Cochrane Haematology, but was not involved in the editorial process for this review.
CB: none known.
AM: has no relevant conflicts of interest to declare. Affiliation with not‐for‐profit organisation: co‐ordination of Section COVRIIN and work in Office of STAKOB (Competence and Treatment Centres for high consequence infectious diseases) at Robert Koch Institute Centre for Biological Threats and Special Pathogens (ZBS), Section Clinical Management and Infection Control.
MG: works as an Intensive Care Medicine Consultant and is member of the CEOsys project, which was funded in 2021 by the Network of University Medicine (Nationales Forschungsnetzwerk der Universitätsmedizin (NUM)) by the Federal Ministry of Education and Research of Germany (Bundesministerium für Bildung und Forschung (BMBF)), grant number 01KX2021, paid to the institution.
FF: works as an Intensive Care Medicine Consultant and is member of the CEOsys project (no direct funding).
MS: has no known conflicts of interest to declare.
Figures
Update of
-
Remdesivir for the treatment of COVID-19.Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD014962. doi: 10.1002/14651858.CD014962. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2023 Jan 25;1:CD014962. doi: 10.1002/14651858.CD014962.pub2. PMID: 34350582 Free PMC article. Updated.
Similar articles
-
Remdesivir for the treatment of COVID-19.Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD014962. doi: 10.1002/14651858.CD014962. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2023 Jan 25;1:CD014962. doi: 10.1002/14651858.CD014962.pub2. PMID: 34350582 Free PMC article. Updated.
-
Colchicine for the treatment of COVID-19.Cochrane Database Syst Rev. 2021 Oct 18;10(10):CD015045. doi: 10.1002/14651858.CD015045. Cochrane Database Syst Rev. 2021. PMID: 34658014 Free PMC article. Review.
-
Janus kinase inhibitors for the treatment of COVID-19.Cochrane Database Syst Rev. 2022 Jun 13;6(6):CD015209. doi: 10.1002/14651858.CD015209. Cochrane Database Syst Rev. 2022. PMID: 35695334 Free PMC article. Review.
-
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence.Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD014963. doi: 10.1002/14651858.CD014963.pub2. Cochrane Database Syst Rev. 2022. PMID: 36385229 Free PMC article. Review.
Cited by
-
Comparative analysis of the safety and effectiveness of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19: a retrospective study from a tertiary hospital in China.Front Pharmacol. 2024 Jul 22;15:1362345. doi: 10.3389/fphar.2024.1362345. eCollection 2024. Front Pharmacol. 2024. PMID: 39104387 Free PMC article.
-
The effect of early remdesivir administration in COVID-19 disease progression in hospitalised patients.Wien Klin Wochenschr. 2024 Aug;136(15-16):458-464. doi: 10.1007/s00508-024-02377-7. Epub 2024 Jun 17. Wien Klin Wochenschr. 2024. PMID: 38884783 Free PMC article.
-
Quality control in SARS-CoV-2 RBD-Fc vaccine production using LC-MS to confirm strain selection and detect contaminations from other strains.Sci Rep. 2024 Apr 26;14(1):9629. doi: 10.1038/s41598-024-59860-4. Sci Rep. 2024. PMID: 38671013 Free PMC article.
-
Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis.Sci Rep. 2024 Apr 23;14(1):9303. doi: 10.1038/s41598-024-59957-w. Sci Rep. 2024. PMID: 38654033 Free PMC article.
-
Personalized Assessment of Mortality Risk and Hospital Stay Duration in Hospitalized Patients with COVID-19 Treated with Remdesivir: A Machine Learning Approach.J Clin Med. 2024 Mar 22;13(7):1837. doi: 10.3390/jcm13071837. J Clin Med. 2024. PMID: 38610602 Free PMC article.
References
References to studies included in this review
Beigel 2020 {published data only}2020‐001052‐18ISRCTN13035264jRCT2031190264
-
- Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 - preliminary report. New England Journal of Medicine 2020;383:1813-26. [CLINICALTRIALS.GOV: NCT04280705] [DOI: 10.1056/NEJMoa2007764] - DOI - PMC - PubMed
-
- EUCTR2020-001052-18-DE. A multicenter, adaptive, randomised blinded controlled trial of the safety and efficacy of investigational therapeutics for the treatment of COVID-19 in hospitalised adults - version for European Union/United Kingdom sites. www.clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2020-001052-1... (first received 27 March 2020). [EUCTR: EUCTR2020-001052-18-DE]
Gottlieb 2021 {published data only}2020‐003510‐12
-
- EUCTR2020-003510-12. A study to test a drug named remdesivir to evaluate the efficacy and safety of the drug in treating patients with COVID-19 in an outpatient setting (non-hospitalised). www.clinicaltrialsregister.eu/ctr-search/trial/2020-003510-12/GB (first received 2 September 2020). [EUCTR: EUCTR2020-003510-12]
-
- Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early remdesivir to prevent progression to severe COVID-19 in outpatients. New England Journal of Medicine 2021;386(4):305-15. [CLINICALTRIALS.GOV: NCT04501952] [DOI: 10.1056/NEJMoa2116846] [EUCTR: 2020-003510-12] - DOI - PMC - PubMed
-
- Hill JA, Paredes R, Vaca C, Mera J, Webb BJ, Perez G, et al. Remdesivir for the treatment of high-risk non-hospitalised individuals with COVID-19: a randomised, double-blind, placebo-controlled trial. Late Breaking Abstracts - Open Forum Infectious Diseases 2021;8(Suppl 1):S806-7.
-
- NCT04501952. Study to evaluate the efficacy and safety of remdesivir (GS-5734™) treatment of coronavirus disease 2019 (COVID-19) in an outpatient setting. clinicaltrials.gov/ct2/show/NCT04501952 (first received 6 August 2020). [CLINICALTRIALS.GOV: NCT04501952]
Mahajan 2021 {published data only}
Spinner 2020 {published data only}EUCTR2020‐000842‐32ISRCTN85762140
-
- Castagna A, Cheong Hui DS, Mullane KM, Jain M, Galli M, Chang SC, et al. Baseline characteristics associated with clinical improvement and mortality in hospitalised patients with moderate COVID-19. Open Forum Infectious Diseases 2020;7(Suppl 1):S340. [DOI: 10.1093/ofid/ofaa439.742] - DOI
-
- Criner GJ, Criner GJ, Ahn MY, Huhn G, Subramanian A, Lumbreras C, et al. 561. Safety of remdesivir vs standard care in patients with moderate Covid-19. Open Forum Infectious Diseases 2020;7(Suppl 1):S345–6.
-
- EUCTR2020-000842-32-ES. This study will test a drug named remdesivir (GS-5734 TM) to evaluate the safety and effectiveness of the drug in treating patients with moderate coronavirus disease 2019 (COVID-19) compared to standard of care treatment. https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000842-32/ES (first received 11 March 2020).
-
- Marty FM, Malhotra P, Gottlieb RL, Tashima KT, Galli M, Chai LYA, et al. Remdesivir vs standard care in patients with moderate Covid-19. Open Forum Infectious Diseases 2020;7(Suppl 1):S166–7.
-
- NCT04292730. Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with moderate coronavirus disease (COVID-19) compared to standard of care treatment. clinicaltrials.gov/ct2/show/results/NCT04292730 (first received 3 March 2020).
Wang 2020 {published data only}
-
- Horby P, Cao B, Wang Y, Wang C. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe pneumonia caused by COVID-19 virus infection: study protocol for a phase 3 randomised, double-blind, placebo-controlled, multicentre trial. Research Square 2020. [DOI: 10.21203/rs.2.24058/v2] - DOI - PMC - PubMed
-
- NCT04257656. A trial of remdesivir in adults with severe COVID-19. clinicaltrials.gov/ct2/show/NCT04257656 (first received 6 February 2020).
-
- Oikonomou K, Ko F. Remdesivir in hospitalised adults with severe COVID-19: lessons learned from the first randomised trial. Journal of Clinical Outcomes Management 2020;27(3):104-6. [DOI: 10.12788/jcom.0002] - DOI
-
- Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395(10236):1569-78. [CLINICALTRIALS.GOV: NCT04257656] [DOI: 10.1016/s0140-6736(20)31022-9] - DOI - PMC - PubMed
WHO Solidarity Canada 2022 {published data only}
-
- NCT04330690. Treatments for COVID-19: Canadian arm of the solidarity trial (CATCO). https://clinicaltrials.gov/ct2/show/NCT04330690 (first received 1 April 2020). [NCT: 04330690]
WHO Solidarity France 2021 {published data only}
-
- Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, et al. Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial. Medrxiv 2022. [DOI: 10.1101/2022.03.30.22273206] - DOI
-
- Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet 2022;22(2):P209-21. [CLINICALTRIALS.GOV: NCT04315948] [DOI: 10.1016/S1473-3099(21)00485-0] [EUCTR: EudraCT2020-000936-23] - DOI - PMC - PubMed
-
- Ader F. Protocol for the discovery trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. BMJ Open 2020;10:e041437. [CLINICALTRIALS.GOV: NCT04315948] [DOI: 10.1136/bmjopen-2020-041437] [EUCTR: EUCTR2020-000936-23] - DOI - PMC - PubMed
-
- EUCTR2020-000936-23-FR. Multi-centre, adaptive, randomised trial of the safety and efficacy of treatments of COVID-19 in hospitalised adults - discovery. www.clinicaltrialsregister.eu/ctr-search/trial/2020-000936-23/FR (first received 9 March 2020). - PMC - PubMed
-
- EUCTR2020-000936-23-PT. Safety and efficacy of treatments of COVID-19 in hospitalised adults (discovery). www.clinicaltrialsregister.eu/ctr-search/trial/2020-000936-23/PT (first received 7 March 2020).
WHO Solidarity Norway 2021 {published data only}
-
- Barratt-Due A, Olsen IC, Henriksen KN, Kåsine T, Lund-Johansen F, Hoel H, et al. Evaluation of remdesivir and hydroxychloroquine on viral clearance in COVID-19 patients: results from the NOR-solidarity randomised trial (preprint). SSRN 2021. [CLINCIALTRIALS.GOV: NCT04321616] [DOI: 10.2139/ssrn.3774182] - DOI
-
- Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, Kåsine T, Lund-Johansen F, Hoel H, et al. Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19: a randomised trial. Annals of Internal Medicine 2021;174(9):1261-9. [CLINICALTRIALS.GOV: NCT04321616] [DOI: 10.7326/M21-0653] - DOI - PMC - PubMed
-
- EUCTR2020-000982-18-NO. A clinical study to evaluate the efficacy of different anti-viral drugs in SARS-CoV-2 infected patients (COVID-19). www.clinicaltrialsregister.eu/ctr-search/trial/2020-000982-18/NO (first received 24 March 2020).
-
- NCT04321616. The efficacy of different anti-viral drugs in (severe acute respiratory syndrome-corona virus-2) SARS-CoV-2. clinicaltrials.gov/ct2/show/NCT04321616 (first received 25 March 2020). [NCT: NCT04321616]
WHO Solidarity Trial Consortium 2022 {published data only}ISRCTN83971151
-
- CTRI/2020/04/024773. A clinical trial to study the effects of additional treatments for patients hospitalised and receiving treatment due to COVID -19. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897 (first received 21 April 2020). [CTRI: CTRI/2020/04/024773]
-
- Deresinski S. Treatment of COVID-19 patients with remdesivir, hydroxychloroquine, lopinavir, or interferon beta-1a. Infectious Disease Alert 2021;40(4).
-
- EUCTR2020-001366-11-IT. An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001366-11/IT (first received 20 April 2020).
-
- EUCTR2020-001366-11-LT. An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001366-11/LT (first received 7 April 2020).
-
- EUCTR2020-001549-38-DE. An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care - WHO-solidarity-Germany. www.clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2020-001549-3... (first received 6 April 2020).
References to studies excluded from this review
Abd‐Elsalam 2021 {published data only}
-
- Abd-Elsalam S, Salama M, Soliman S, Naguib AA, Ibrahim IS, Torky M, et al. Remdesivir efficacy in COVID-19 treatment: a randomised controlled trial. American Journal of Tropical Medicine and Hygiene 2021;106(3):886-90. [CLINCALTRIALS.GOV: NCT04345419] [DOI: 10.4269/ajtmh.21-0606] - DOI - PMC - PubMed
Ader 2020 {published data only}
Ader 2021 {published data only}
-
- Ader F, PeiMer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A, et al. Antiviral drugs inhospitalised patients with COVID-19 - the DisCoVeRy trial. Medrxiv 2021. [CLINICALTRIALS.GOV: NCT04315948] [DOI: 10.1101/2021.01.08.20248149] - DOI
Alpern 2020 {published data only}
Anderson 2021 {published data only}
Antinori 2020 {published data only}
-
- Antinori S, Cossu MV, Ridolfo AL, Rech R, Bonazzetti C, Pagani G, et al. Compassionate remdesivir treatment of severe COVID-19 pneumonia in intensive care unit (ICU) and non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status. Pharmacological Research 2020;158:104899. [DOI: 10.1016/j.phrs.2020.104899] - DOI - PMC - PubMed
Banerjee 2020 {published data only}
-
- Banerjee I, Mohabeer P, Shukla A, Kashyap A, Robinson J. COVID-19: recent advances in epidemiology, virology, etiopathogenesis, clinical trials and vaccine development. Journal of Biomedical Sciences 2020;7(1):18-27.
CTRI/2020/12/029613 {published data only}
-
- CTRI/2020/12/029613. Drug to prevent lung injury secondary to COVID 19. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=50026 (first received 7 December 2020).
CTRI/2020/12/029615 {published data only}
-
- CTRI/2020/12/029615. Remdesivir plus tocilizumab efficacy trial in moderate to severe COVID-19 patients. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=49731 (first received 7 December 2020).
CTRI/2021/01/030830 {published data only}
-
- CTRI/2021/01/030830. Therapeutics for inpatients with COVID-19 (TICO). www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=52067 (first received 29 January 2021).
CTRI/2021/12/038637 {published data only}
-
- CTRI/2021/12/038637. A clinical trial to study the safety and efficacy of a drug, DESREM LQTM in patients with moderate to severe COVID-19. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2021/12/038637 (first received 24 December 2021).
CTRI/2021/12/039011 {published data only}
-
- CTRI/2021/12/039011. A study to assess the safety and efficacy of remdesivir in COVID-19 infected Indian patients. trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2021/12/039011 (first received 29 December 2021).
CTRI/2022/03/041252 {published data only}
-
- CTRI/2022/03/041252. A clinical study to understand the effect of remdesivir intravenous injection in hospitalised moderate to severe COVID-19 patients. www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=65800 (first received 22 March 2022).
Deresinski 2020 {published data only}
-
- Deresinski S. Remdesivir and COVID-19. Infectious Disease Alert 2020;39(10).
Elliott 2020 {published data only}
-
- Elliott W, Chan J. Remdesivir injection. Internal Medicine Alert 2020;42(11).
Elliott 2021 {published data only}
-
- Elliot W, Chan J. Remdesivir injection and baricitinib tablets. Internal Medicine Alert 2021.
EUCTR2020‐000841‐15‐ES {published data only}
-
- EUCTR2020-000841-15-ES. A phase 3 randomised study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with severe COVID-19 [Estudio de fase 3 aleatorizado para evaluar la seguridad y la actividad antiviral de remdesivir (GS-5734™) en participantes con infección grave por el COVID-19]. www.clinicaltrialsregister.eu/ctr-search/trial/2020-000841-15/ES (first received 11 March 2020).
EUCTR2020‐000936‐23 {published data only}
-
- EUCTR2020-000936-23. Multi-centre, adaptive, randomised trial of the safety and efficacy of treatments of COVID-19 in hospitalised adults - DisCoVeRy. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:202... (first received 9 March 2020).
Euctr2020‐003510‐12‐dk {published data only}
-
- EUCTR2020-003510-12-DK. A study to test a drug named remdesivir to evaluate the efficacy and safety of the drug in treating patients with COVID-19 in an outpatient setting (non-hospitalised). www.clinicaltrialsregister.eu/ctr-search/search?query=EUCTR2020-003510-1... (first received 31 August 2020).
EUCTR2020‐004928‐42‐HU {published data only}
-
- EUCTR2020-004928-42-HU. Clinical trial of remdesivir in COVID-19 patients. https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004928-42/HU (first received 12 October 2020). [EUCTR: 2020-004928-42]
Goldberg 2021 {published data only}
Goldman 2020 {published data only}
-
- Goldman JD, Lye DCB, Hui DS, Marks KM, Bruno R, Montejano R, et al. Remdesivir for 5 or 10 days in patients with severe COVID-19. New England Journal of Medicine 2020;383:1827-37. [CLINICALTRIALS.GOV: NCT04292899] [DOI: 10.1056/NEJMoa2015301] - DOI - PMC - PubMed
-
- ISRCTN15874265. Study to assess the safety and effectiveness of remdesivir in people with severe COVID-19. www.isrctn.com/ISRCTN15874265 (first received 29 October 2020).
-
- NCT04292899. Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with severe coronavirus disease (COVID-19). clinicaltrials.gov/ct2/show/NCT04292899 (first received 3 March 2020).
Goldman 2020a {published data only}
-
- Goldman JD, Lye DCB, Hui DS‐C, Marks K, Bruno R, Montejano R, et al. Impact of baseline alanine aminotransferase levels on the safety and efficacy of remdesivir in severe COVID-19 patients. Hepatology 2020;72:279A.
Grein 2020 {published data only}
Grundmann 2022 {published data only}
IRCT20151227025726N28 {published data only}
-
- IRCT20151227025726N28. Evaluating the effects of remdesivir in severe COVID-19 in hospitalised patients. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20151227025726N28 (first received 21 October 2021).
IRCT20210324050760N1 {published data only}
-
- IRCT20210324050760N1. Effect of remdesivir in treatment of COVID-19. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20210324050760N1 (first received 21 April 2021).
ISRCTN15874265 {published data only}
-
- ISRCTN15874265. Study to assess the safety and effectiveness of remdesivir in people with severe COVID-19. www.isrctn.com/ISRCTN15874265 (first received 29 October 2020).
ISRCTN85762140 {published data only}
-
- ISRCTN85762140. Study to assess the safety and effectiveness of remdesivir in people with moderate COVID-19. www.isrctn.com/ISRCTN85762140 (first received 2 November 2020).
Jang 2021 {published data only}
Kalil 2021 {published data only}
-
- Elliott W, Chan J. Remdesivir injection and baricitinib tablets. Internal Medicine Alert 2021;43(1).
-
- Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, ACTT-2 study group members. Baricitinib plus remdesivir for hospitalized adults with COVID-19. New England Journal of Medicine 2020;384(9):795-807. [CLINICALTRIALS.GOV: NCT04401579] [DOI: 10.1056/NEJMoa2031994] - DOI - PMC - PubMed
-
- NCT04401579. Adaptive COVID-19 treatment trial 2 (ACTT-2). clinicaltrials.gov/ct2/show/NCT04401579 (first received 26 May 2020).
Lapadula 2020 {published data only}
LBCTR2020043495 {published data only}
-
- LBCTR2020043495. An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care. https://lbctr.moph.gov.lb/Trials/Details/4522 (first received 22 April 2020). [LBCTR: 2020043495]
Medical Brief {published data only}
-
- Medical Brief. Remdesivir for COVID-19 improves time to recovery – peer-reviewed adaptive COVID-19 teatment trial. www.medicalbrief.co.za/archives/remdesivir-for-covid-19-improves-time-to... 2020;304.
NCT04252664a {published data only}
-
- NCT04252664. A trial of remdesivir in adults with mild and moderate COVID-19. clinicaltrials.gov/ct2/show/NCT04252664 (first received 5 February 2020).
NCT04256395 {published data only}
-
- NCT04256395. Efficacy of a self-test and self-alert mobile applet in detecting susceptible infection of COVID-19 (COVID-19). clinicaltrials.gov/ct2/show/NCT04256395 (first received 5 February 2020).
NCT04280705 {published data only}
-
- NCT04280705. Adaptive COVID-19 treatment trial (ACTT). clinicaltrials.gov/ct2/show/NCT04280705 (first received 21 February 2020).
NCT04292899 {published data only}
-
- NCT04292899. Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with severe coronavirus disease (COVID-19). clinicaltrials.gov/ct2/show/NCT04292899 (first received 3 March 2020).
NCT04302766 {published data only}
-
- NCT04302766. Expanded access remdesivir (RDV; GS-5734™). clinicaltrials.gov/ct2/show/NCT04302766 (first received 10 March 2020).
NCT04321928 {published data only}
-
- NCT04321928. Personalised health education against the health damage of novel coronavirus (COVID-19) outbreak in Hungary (PROACTIVE-19). clinicaltrials.gov/ct2/show/NCT04321928 (first received 25 March 2020).
NCT04323761 {published data only}
-
- NCT04323761. Expanded access treatment protocol: temdesivir (RDV; GS-5734) for the treatment of SARS-CoV2 (CoV) infection (COVID-19). clinicaltrials.gov/ct2/show/NCT04323761 (first received 27 March 2020).
NCT04353596 {published data only}
-
- NCT04353596. Stopping ACE-inhibitors in COVID-19 (ACEI-COVID). clinicaltrials.gov/ct2/show/record/NCT04353596?view=record (first received 20 April 2020).
NCT04401579 {published data only}
-
- NCT04401579. Adaptive COVID-19 treatment trial 2 (ACTT-2). clinicaltrials.gov/ct2/show/NCT04401579 (first received 26 May 2020).
NCT04410354 {published data only}
-
- NCT04410354. Study of merimepodib in combination with remdesivir in adult patients with advanced COVID-19. clinicaltrials.gov/ct2/show/NCT04410354 (first received 1 June 2020).
NCT04480333 {published data only}
-
- NCT04480333. Safety, tolerability and pharmacokinetics of inhaled nanoparticle formulation of remdesivir (GS-5734) and NA-831. clinicaltrials.gov/ct2/show/NCT04480333 (first received 21 July 2020).
NCT04488081 {published data only}
-
- NCT04488081. I-SPY COVID-19 trial: an adaptive platform trial for critically ill patients (I-SPY_COVID). clinicaltrials.gov/ct2/show/NCT04488081 (first received 27 July 2020).
NCT04492475 {published data only}
-
- NCT04492475. Adaptive COVID-19 treatment trial 3 (ACTT-3). clinicaltrials.gov/ct2/show/NCT04492475 (first received 30 July 2020).
NCT04501978 {published data only}
-
- NCT04501978. ACTIV-3: therapeutics for inpatients with COVID-19 (TICO). clinicaltrials.gov/ct2/show/NCT04501978 (first received 6 August 2020).
NCT04518410 {published data only}
-
- NCT04518410. ACTIV-2: a study for outpatients with COVID-19. clinicaltrials.gov/ct2/show/NCT04518410 (first received 19 August 2020).
NCT04539262 {published data only}
-
- NCT04539262. Study in participants with early stage coronavirus disease 2019 (COVID-19) to evaluate the safety, efficacy, and pharmacokinetics of remdesivir administered by inhalation. clinicaltrials.gov/ct2/show/NCT04539262 (first received 4 September 2020).
NCT04583956 {published data only}
-
- NCT04583956. ACTIV-5 / big effect trial (BET-A) for the treatment of COVID-19. clinicaltrials.gov/ct2/show/NCT04583956 (first received 12 October 2020).
NCT04583969 {published data only}
-
- NCT04583969. ACTIV-5 / big effect trial (BET-B) for the treatment of COVID-19. clinicaltrials.gov/ct2/show/NCT04583969 (first received 12 October 2020).
NCT04610541 {published data only}
-
- NCT04610541. REMdesivir-HU clinical study and severe COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04610541 (first received 30 October 2020).
NCT04640168 {published data only}
-
- NCT04640168. Adaptive COVID-19 treatment trial 4 (ACTT-4). clinicaltrials.gov/ct2/show/NCT04640168 (first received 23 November 2020).
NCT04647695 {published data only}
-
- NCT04647695. IFN-beta 1b and remdesivir for COVID19. clinicaltrials.gov/ct2/show/NCT04647695 (first received 1 December 2020).
NCT04678739 {published data only}
-
- NCT04678739. Efficacy and safety of remdesivir and tociluzumab for the management of severe COVID-19: a randomised controlled trial. clinicaltrials.gov/ct2/show/NCT04678739 (first received 22 December 2020).
NCT04693026 {published data only}
-
- NCT04693026. Efficacy of remdisivir and baricitinib for the treatment of severe COVID 19 patients. clinicaltrials.gov/ct2/show/NCT04693026 (first received 5 January 2021).
NCT04713176 {published data only}
-
- NCT04713176. Efficacy and safety of DWJ1248 with remdesivir in severe COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04713176 (first received 19 January 2021).
NCT04728880 {published data only}
-
- NCT04728880. Remdesivir in adults with COVID-19: Mansoura university hospital experience. clinicaltrials.gov/ct2/show/NCT04728880 (first received 28 January 2021).
NCT04746183 {published data only}
-
- NCT04746183. AGILE (early phase platform trial for COVID-19). clinicaltrials.gov/ct2/show/NCT04746183 (first received 9 February 2021).
NCT04832880 {published data only}
-
- NCT04832880. Factorial randomised trial of rendesivir and baricitinib plus dexamethasone for COVID-19 (the AMMURAVID Trial) (AMMURAVID). clinicaltrials.gov/ct2/show/NCT04832880 (first received 6 April 2021).
NCT04847622 {published data only}
-
- NCT04847622. Study to evaluate the clinical outcomes in adults with COVID-19 who have been treated with remdesivir. clinicaltrials.gov/ct2/show/NCT04847622 (first received 19 April 2021).
Olender 2020 {published data only}
-
- NCT04292899. Study to evaluate the safety and antiviral activity of remdesivir (GS-5734™) in participants with severe coronavirus disease (COVID-19). clinicaltrials.gov/ct2/show/NCT04292899 (first received 3 March 2020).
-
- Olender SA, Perez KK, Go AS, Balani B, Price-Haywood EG, Shah NS, et al. Remdesivir for severe coronavirus disease 2019 (COVID- 19) versus a cohort receiving standard of care. Clinical Infectious Diseases 2020;73(11):e4166-74. [CLINICALTRIALS.GOV: NCT04292899] [DOI: 10.1093/cid/ciaa1041] [EUPAS: EUPAS34303] - DOI - PMC - PubMed
Olender 2021 {published data only}
Padilla 2022 {published data only}
-
- Padilla S, Polotskaya K, Fernández M, Gonzalo-Jiménez N, la Rica A, García JA, et al. Survival benefit of remdesivir in hospitalised COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation. Journal of Antimicrobial Chemotherapy 2022;77:2257-64. [DOI: 10.1093/jac/dkac144] - DOI - PubMed
Pan 2020 {published data only}
Pan 2021 {published data only}
-
- Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Karim QA, WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19 - Interim WHO solidarity trial results. New England Journal of Medicine 2021;384:497-511. [DOI: 10.1056/NEJMoa2023184] [EUCTR2020-001366-11] [ISRCTN83971151] [NCT04315948] - DOI - PMC - PubMed
PER‐101‐20 {published data only}
-
- PER-101-20. Randomised master protocol for immune modulators for treating COVID-19. www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=101-20 (first received 30 December 2020).
Rosas 2021 {published data only}
-
- NCT04409262. A study to evaluate the efficacy and safety of remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalised participants with severe COVID-19 pneumonia (REMDACTA). clinicaltrials.gov/ct2/show/NCT04409262 (first received 1 June 2020).
Saito 2020 {published data only}
Shakir 2022 {published data only}
-
- Shakir A, Bhasin N, Swami R, Mehta K, Sinha S, Ali SS, et al. Renal and hepatic outcomes after remdesivir therapy in coronavirus disease-2019-positive patients with renal dysfunction at baseline or after starting therapy. Saudi Journal of Kidney Diseases and Transplantation 2021;32(4):1034-42. - PubMed
Shih 2020 {published data only}
Soto 2020 {published data only}
-
- Soto A, Quiñones-Laveriano DM, Garcia PJ, Gotuzzo E, Henao-Restrepo AM. Rapid responses to the COVID-19 pandemic through science and global collaboration: the solidarity clinical trial [Respuestas rápidas a la pandemia de COVID-19 a través de la ciencia y la colaboración global: el ensayo clínico solidaridad]. Revista Peruana de Medicina Experimental y Salud Pública 2020;37:356-60. [DOI: 10.17843/rpmesp.2020.372.5546] - DOI - PubMed
Sun 2020 {published data only}
Tran 2020 {published data only}
-
- Tran B. Early data on remdesivir for severe COVID-19: a promising start? Internal Medicine Alert 2020;42(13).
Winstead 2021 {published data only}
-
- Winstead RJ, Christensen J, Sterling S, Morales M, Kumar D, Bryson A, et al. Effect of remdesivir on COVID-19 PCR positivity and cycle threshold in kidney transplant recipients. Transplantology 2021;2(3):291-3. [DOI: 10.3390/transplantology2030028] - DOI
References to studies awaiting assessment
NCT04596839 {published data only}
-
- NCT04596839. Antiviral activity and safety of remdesivir in Bangladeshi patients with severe coronavirus disease (COVID-19). https://clinicaltrials.gov/ct2/show/NCT04596839 (first received 22 October 2020).
REDPINE 2022 {published data only}EUCTR2020‐005416‐22
-
- EUCTR2020-005416-22. A phase 3 study of remdesivir in participants with severe renal impairment who are in hospital for COVID-19. www.clinicaltrialsregister.eu/ctr-search/trial/2020-005416-22/PT#P (first received 24 February 2021).
-
- NCT04745351. Study to evaluate the efficacy and safety of remdesivir in participants with severely reduced kidney function who are hospitalised for coronavirus disease 2019 (COVID-19) (REDPINE). clinicaltrials.gov/ct2/show/NCT04745351 (first received 9 February 2021).
References to ongoing studies
IRCT20210709051824N1 {published data only}IRCT20210709051824N1
-
- IRCT20210709051824N1. Assessment of utility of remdesivir in patients with acute kidney injury or cronic kidney disease in admitted COVID-19 patients. trialsearch.who.int/Trial2.aspx?TrialID=IRCT20210709051824N1 (first received 22 December 2021).
NCT04252664 {published data only}
-
- NCT04252664. A trial of remdesivir in adults with mild and moderate COVID-19. clinicaltrials.gov/ct2/show/NCT04252664 (first received 5 February 2020).
NCT04351724 {published data only}
-
- NCT04351724. Austrian coronavirus adaptive clinical trial (COVID-19) (ACOVACT). clinicaltrials.gov/ct2/show/NCT04351724 (first received 17 April 2020).
NCT04843761 {published data only}
-
- NCT04843761. ACTIV-3b: therapeutics for severely ill inpatients with COVID-19 (TESICO). clinicaltrials.gov/ct2/show/NCT04843761 (first received 14 April 2021).
NCT04978259 {published data only}
-
- NCT04978259. Long-term follow-up of a randomised multicenter trial on impact of long-COVID in hospitalised COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04978259 (first received 27 July 2021).
Additional references
Al‐Abdouh 2021
Angamo 2022
Beckermann 2022
-
- Beckermann R, Gori A, Jeyakumar S, Malin JJ, Paredes R, Póvoa P, et al. Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis. Scientific Reports 2022;12(1):9622. [DOI: 10.1038/s41598-022-13680-6] - DOI - PMC - PubMed
Brandal 2021
Buitrago‐Garcia 2022
-
- Buitrago-Garcia D, Ipekci AM, Heron L, Imeri H, Araujo-Chaveron L, Arevalo-Rodriguez I, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: Update of a living systematic review and meta-analysis. PLOS Medicine 2022;19(5):e1003987. [DOI: ] - PMC - PubMed
CDC 2022
-
- Centers for Disease Control and Prevention. Symptoms of COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html (accessed 6 June 2022).
CEOsys 2021
-
- German COVID-19 evidence-ecosystem. www.covid-evidenz.de (accessed prior to 22 July 2021).
Choy 2020
Cochrane LSR
-
- Guidance for the production and publication of Cochrane living systematic reviews: Cochrane Reviews in living mode. Available from community.cochrane.org/review-production/production-resources/living-sys... (accessed 16 March 2022 ).
COMET 2020
-
- Core outcome set developers’ response to COVID-19. www.comet-initiative.org/Studies/Details/1538 (accessed 2 November 2020).
Covidence 2021 [Computer program]
-
- Covidence. Version accessed 15 January 2021. Melbourne, Australia: Veritas Health Innovation, 2021. Available at covidence.org.
CRD42021238065
-
- CRD42021238065. Remdesivir for the treatment of hospitalized adults COVID-19 patients (part of German Ecosystem CEO-sys). www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021238065 (first received 26 February 2021).
Deeks 2020
-
- Deeks JJ, Higgins JP, Altman DG, editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Available from training.cochrane.org/handbook.
de Vries 2022
de Wit 2020
Eldridge 2016
-
- Eldridge S, Campbell M, Campbell M, Dahota A, Giraudeau B, Higgins JT, et al. Revised Cochrane risk of bias tool for randomized trials (RoB 2.0). Additional considerations for cluster-randomized trials. www.riskofbias.info/welcome/rob-2-0-tool/rob-2-for-cluster-randomized-tr... (accessed 1 March 2021).
EMA 2020
-
- European Medicines Agency. Summary on compassionate use remdesivir Gilead. www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivi... (accessed 9 May 2022).
EMA 2022
-
- European Medicines Agency. COVID-19 treatments. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-thr... (accessed 6 June 2022).
EUA 2020
-
- European Commission authorises first treatment against COVID-19. eeas.europa.eu/headquarters/headquarters-homepage/82135 (accessed 10 March 2021).
EUA 2021
-
- Fact sheet for health care providers Emergency Use Authorisazation (EUA) of remdesivir (GS-5734™). www.askgileadmedical.com/downloads/pdfs/EUA%20Fact%20Sheet%20for%20HCPs.pdf (accsessed 10 March 2021).
EUA 2022
-
- Emergency Use Authorization (EUA) for remdesivir, an unapproved product Center for Drug Evaluation and Research (CDER) Memorandum. https://www.fda.gov/media/155772/download (accessed 6 May 2022).
FDA 2022a
-
- US Food and Drug Administration. Coronavirus (COVID-19) - Drugs. https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid... (accessed 6 June 2022).
FDA 2022b
-
- US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Approves First COVID-19 Treatment for Young Children. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19... 25 April 2022.
Funk 2021
-
- Funk T, Pharris A, Spiteri G, Bundle N, Melidou A, Carr M, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Eurosurveillance 2021;26(16):2100348. [DOI: 10.2807/1560-7917.ES.2021.26.16.2100348] - DOI - PMC - PubMed
Gautret 2020
Griesel 2022
Higgins 2003
Higgins 2022a
-
- Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.
Higgins 2022b
-
- Higgins JP, Eldridge S, Li T. Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.
Higgins 2022c
-
- Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.
Higgins 2022d
-
- Higgins JP, Tianging L, Deeks JJ, editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022. Available from training.cochrane.org/handbook.
Huang 2020
Izcovich 2022
-
- Izcovich A, Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Kum E, et al. Adverse effects of remdesivir, hydroxychloroquine and liponavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials. BMJ Open 2022;12(3):e048502.2. [DOI: 10.1136/bmjopen-2020-048502] - DOI - PMC - PubMed
Johns Hopkins 2022
-
- Johns Hopkins Coronavirus Resource Center. Mortality Analyses. https://coronavirus.jhu.edu/data/mortality (accessed 6 June 2022).
Kaka 2022
-
- Kaka AS, MacDonald R, Linskens EJ, Langsetmo L, Vela K, Duan-Porter W, et al. Major Update 2: Remdesivir for adults with COVID-19: a living systematic review and meta-analysis for the American College of Physicians Practice Points. Annals of Internal Medicine 2022;175(5):701-9. [DOI: ] - PMC - PubMed
Karagiannidis 2020
-
- Karagiannidis C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schillinger G, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respiratory Medicine 2020;8:853-62. [DOI: 10.1016/ S2213-2600(20)30316-7] - PMC - PubMed
Kramer 2022
Kreuzberger 2021
Lauer 2020
Lee 2022
Lewnard 2022
Li 2020
-
- Li T, Higgins JP, Deeks JJ (editors). Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Available from training.cochrane.org/handbook. [EPUB: training.cochrane.org/handbook]
Liang 2020
Lo 2017
MAGICapp [Computer program]
-
- MAGICapp. Brønnøysund (NOR): Norwegian MAGIC Evidence Ecosystem Foundation (powered by UserVoice Inc.), (accessed 25 February 2021). Available at magicapp.org.
McGuigan 2006
-
- McGuigan C, Hassan-Abdallah A, Srinivasan S, Wang Y, Siddiqui A, Daluge SM, et al. Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives. Journal of Medicinal Chemistry 2006;49(24):7215-26. [DOI: 10.1021/jm060776w] - DOI - PubMed
Microsoft 2018 [Computer program]
-
- Mircosoft Excel. Microsoft Corporation, 2018. Available at office.microsoft.com/excel.
Moher 2009
NCT04431453
-
- Gilead Science. Study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of remdesivir (GS-5734™) in participants from birth to < 18 years of age with coronavirus disease 2019 (COVID-19) (CARAVAN). https://www.clinicaltrials.gov/ct2/show/study/NCT04431453 (first received 16 June 2020).
NICE guideline 2021
-
- National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19. https://www.nice.org.uk/guidance/NG191 2021 (last updated 19 May 2022). - PubMed
NIH guideline 2022
-
- National Institutes of Health, COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/ (accessed 6 June 2022).
Nyberg 2022
Parmar 1998
Piechotta 2020
-
- Piechotta V, Valk SJ, Chai KL, Wood EM, Lamikanra A, Kimber C, et al. Safety and effectiveness of convalescent plasma or hyperimmune globulin for people with COVID-19: a rapid review. OSF Registries 2020. [DOI: 10.17605/OSF.IO/DWF53] - DOI - PMC - PubMed
Piechotta 2021
-
- Piechotta V, Iannizzi C, Chai KL, Valk SJ, Kimber C, Dorando E, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review. Cochrane Database of Systematic Reviews 2021, Issue 5. Art. No: CD013600. [DOI: 10.1002/14651858.CD013600.pub4] - DOI - PMC - PubMed
Potere 2020
-
- Potere N, Valeriani E, Candeloro M, Tana M, Porreca E, Abbate A, et al. A higher mortality rate and long ventilation times differentiate COVID-19 from severe respiratory infections in flu waves [Eine höhere Letalität und lange Beatmungsdauer unterscheiden COVID-19 von schwer verlaufenden Atemwegsinfektionen in Grippewellen]. Critical Care 2020;24(1):389. [DOI: 10.25646/7111] - DOI
RevMan Web 2021 [Computer program]
-
- Review Manager Web (RevMan Web). Version 3.4.0. The Cochrane Collaboration, 2021. Available at revman.cochrane.org.
Richard 2021
-
- Richard SA, Epsi NJ, Pollett S, Lindholm DA, Malloy AMW, Maves R, et al. Performance of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus) instrument in patients with coronavirus disease 2019. Open Forum Infectious Diseases 2021;8(12):ofab517. [DOI: 10.1093/ofid/ofab517] - DOI - PMC - PubMed
Richardson 2020
Santesso 2020
Schünemann 2021
-
- Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.
Sheahan 2017
Sheahan 2020
Siegel 2017
-
- Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, Zhang L, et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. Journal of Medicinal Chemistry 2017;60(5):1648-61. [DOI: 10.1021/acs.jmedchem.6b01594] - DOI - PubMed
Skoetz 2020
-
- Skoetz N, Goldkuhle M, Van Dalen EC, Akl EA, Trivella M, Mustafa RA, et al. GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and evidence profiles. Journal of Clinical Epidemiology 2020;118:124-31. [DOI: 10.1016/j.jclinepi.2019.10.015] - DOI - PubMed
Sterne 2019
Stevens 2022
-
- Stevens LJ, Pruijssers AJ, Lee HW, Gordon CJ, Tchesnokov EP, Gribble J, et al. Mutations in the SARS-CoV-2 RNA dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms. Science Translational Medicine 2022 Aug 3 [Epub ahead of print]. [DOI: 10.1126/scitranslmed.abo0718] - DOI - PMC - PubMed
Struyf 2021
-
- Struyf T, Deeks JJ, Dinnes J, Takwoingi Y, Davenport C, Leeflang MM, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database of Systematic Reviews 2021, Issue 2. Art. No: CD013665. [DOI: 10.1002/14651858.CD013665.pub2] - DOI - PMC - PubMed
Tanni 2022
Thiruchelvam 2022
Tierney 2007
Vangeel 2022
Vegivinti 2022
Wagner 2021
Wang 2020
WHO 2003
-
- World Health Organization. Cumulative number of reported probable cases of SARS. https://www.who.int/publications/m/item/summary-of-probable-sars-cases-w... (accessed 3 June 2022).
WHO 2019
-
- World Health Organization. Middle East respiratory syndrome coronavirus (MERSCoV). https://www.who.int/health-topics/middle-east-respiratory-syndrome-coron... (accessed 3 June 2022).
WHO 2020a
-
- World Health Organization. Timeline: WHO's COVID-19 response. www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-time... (accessed 3 June 2022).
WHO 2020b
-
- World Health Organization. Estimating mortality from COVID-19 - scientific brief. www.who.int/publications/i/item/WHO-2019-nCoV-Sci-Brief-Mortality-2020.1 (accessed 3 June 2022).
WHO 2020c
WHO 2022a
-
- World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. covid19.who.int (accessed 3 June 2022).
WHO 2022b
-
- Tracking SARS-CoV-2 variants. https://www.who.int/activities/tracking-SARS-CoV-2-variants (accessed 6 June 2022).
WHO 2022c
-
- World Health Organization. Therapeutics and COVID-19: living guideline. www.who.int/publications/i/item/therapeutics-and-covid-19-living-guideline (accessed 6 May 2022). - PubMed
WHO living guideline 2022
-
- Geneva: World Health Organization. Therapeutics and COVID-19: Living guideline. WHO/2019-nCoV/therapeutics/2022.3 22 April 2022.
Williamson 2020a
Williamson 2020b
Wolter 2022
References to other published versions of this review
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous